Cambria Investment Management L.P. raised its stake in shares of Nu Skin Enterprises, Inc. (NYSE:NUS) by 1.2% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 30,891 shares of the company’s stock after buying an additional 378 shares during the period. Cambria Investment Management L.P. owned 0.06% of Nu Skin Enterprises worth $1,716,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in NUS. Creative Planning boosted its stake in Nu Skin Enterprises by 38.5% in the first quarter. Creative Planning now owns 1,800 shares of the company’s stock valued at $100,000 after buying an additional 500 shares during the period. TrimTabs Asset Management LLC boosted its stake in Nu Skin Enterprises by 88.7% in the first quarter. TrimTabs Asset Management LLC now owns 2,349 shares of the company’s stock valued at $130,000 after buying an additional 1,104 shares during the period. Independent Portfolio Consultants Inc. boosted its stake in Nu Skin Enterprises by 1.7% in the first quarter. Independent Portfolio Consultants Inc. now owns 2,375 shares of the company’s stock valued at $132,000 after buying an additional 40 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Nu Skin Enterprises by 23.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,506 shares of the company’s stock valued at $139,000 after buying an additional 468 shares during the period. Finally, LS Investment Advisors LLC boosted its stake in Nu Skin Enterprises by 1,022.1% in the first quarter. LS Investment Advisors LLC now owns 3,658 shares of the company’s stock valued at $203,000 after buying an additional 3,332 shares during the period. 86.65% of the stock is currently owned by institutional investors.
Shares of Nu Skin Enterprises, Inc. (NUS) traded down 0.56% on Tuesday, reaching $59.07. The company’s stock had a trading volume of 376,635 shares. Nu Skin Enterprises, Inc. has a 12-month low of $42.97 and a 12-month high of $66.04. The firm has a 50 day moving average price of $56.80 and a 200-day moving average price of $53.05. The stock has a market cap of $3.12 billion, a PE ratio of 19.61 and a beta of 1.36.
Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings data on Wednesday, May 3rd. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.01. The business had revenue of $499.10 million for the quarter, compared to analyst estimates of $493.65 million. Nu Skin Enterprises had a return on equity of 23.45% and a net margin of 7.48%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.42 earnings per share. Equities research analysts expect that Nu Skin Enterprises, Inc. will post $3.12 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 14th. Stockholders of record on Friday, May 26th were issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date was Wednesday, May 24th. Nu Skin Enterprises’s dividend payout ratio is presently 48.48%.
WARNING: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://sportsperspectives.com/2017/06/20/nu-skin-enterprises-inc-nus-position-raised-by-cambria-investment-management-l-p.html.
Several research firms recently commented on NUS. Zacks Investment Research raised Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research report on Saturday, February 25th. ValuEngine raised Nu Skin Enterprises from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. Pivotal Research reaffirmed a “buy” rating and set a $65.00 price objective on shares of Nu Skin Enterprises in a research report on Thursday, May 4th. Finally, Sidoti cut Nu Skin Enterprises from a “buy” rating to a “neutral” rating and set a $59.00 target price on the stock. in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $59.00.
In other news, General Counsel D Matthew Dorny sold 8,000 shares of the stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $58.32, for a total value of $466,560.00. Following the transaction, the general counsel now directly owns 53,730 shares of the company’s stock, valued at $3,133,533.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 24,000 shares of company stock worth $1,360,080 over the last three months. Corporate insiders own 5.20% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.